Monoclonal Antibody Therapies for High Risk Neuroblastoma

Wayne L Furman Department of Oncology, St. Jude Children’s Research Hospital, Memphis, TN, USACorrespondence: Wayne L FurmanDepartment of Oncology, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USATel +1-901-595-2403Fax +1– 901-521-9...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Furman WL
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	immunotherapy neuroblastoma anti-disialoganglioside anti-gd2 chimeric effector cells Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/4d92fc6f80074bf6bbc35d6506e3485d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4d92fc6f80074bf6bbc35d6506e3485d
record_format	dspace
spelling	oai:doaj.org-article:4d92fc6f80074bf6bbc35d6506e3485d2021-12-02T15:47:51ZMonoclonal Antibody Therapies for High Risk Neuroblastoma1177-5491https://doaj.org/article/4d92fc6f80074bf6bbc35d6506e3485d2021-06-01T00:00:00Zhttps://www.dovepress.com/monoclonal-antibody-therapies-for-high-risk-neuroblastoma-peer-reviewed-fulltext-article-BTThttps://doaj.org/toc/1177-5491Wayne L Furman Department of Oncology, St. Jude Children’s Research Hospital, Memphis, TN, USACorrespondence: Wayne L FurmanDepartment of Oncology, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USATel +1-901-595-2403Fax +1– 901-521-9005Email wayne.furman@stjude.orgAbstract: Monoclonal antibodies (mAbs) are part of the standard of care for the treatment of many adult solid tumors. Until recently none have been approved for use in children with solid tumors. Neuroblastoma (NB) is the most common extracranial solid tumor in children. Those with high-risk disease, despite treatment with very intensive multimodal therapy, still have poor overall survival. Results of treatment with an immunotherapy regimen using a chimeric (human/mouse) mAb against a cell surface disialoganglioside (GD2) have changed the standard of care for these children and resulted in the first approval of a mAb for use in children with solid tumors. This article will review the use of the various anti-GD2 mAbs in children with NB, methods that have been or are being evaluated for enhancing their efficacy, as well as review other promising antigenic targets for the therapeutic use of mAbs in children with NB.Keywords: immunotherapy, neuroblastoma, anti-disialoganglioside, anti-GD2, chimeric, effector cellsFurman WLDove Medical Pressarticleimmunotherapyneuroblastomaanti-disialogangliosideanti-gd2chimericeffector cellsMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol Volume 15, Pp 205-219 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	immunotherapy neuroblastoma anti-disialoganglioside anti-gd2 chimeric effector cells Medicine (General) R5-920
spellingShingle	immunotherapy neuroblastoma anti-disialoganglioside anti-gd2 chimeric effector cells Medicine (General) R5-920 Furman WL Monoclonal Antibody Therapies for High Risk Neuroblastoma
description	Wayne L Furman Department of Oncology, St. Jude Children’s Research Hospital, Memphis, TN, USACorrespondence: Wayne L FurmanDepartment of Oncology, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USATel +1-901-595-2403Fax +1– 901-521-9005Email wayne.furman@stjude.orgAbstract: Monoclonal antibodies (mAbs) are part of the standard of care for the treatment of many adult solid tumors. Until recently none have been approved for use in children with solid tumors. Neuroblastoma (NB) is the most common extracranial solid tumor in children. Those with high-risk disease, despite treatment with very intensive multimodal therapy, still have poor overall survival. Results of treatment with an immunotherapy regimen using a chimeric (human/mouse) mAb against a cell surface disialoganglioside (GD2) have changed the standard of care for these children and resulted in the first approval of a mAb for use in children with solid tumors. This article will review the use of the various anti-GD2 mAbs in children with NB, methods that have been or are being evaluated for enhancing their efficacy, as well as review other promising antigenic targets for the therapeutic use of mAbs in children with NB.Keywords: immunotherapy, neuroblastoma, anti-disialoganglioside, anti-GD2, chimeric, effector cells
format	article
author	Furman WL
author_facet	Furman WL
author_sort	Furman WL
title	Monoclonal Antibody Therapies for High Risk Neuroblastoma
title_short	Monoclonal Antibody Therapies for High Risk Neuroblastoma
title_full	Monoclonal Antibody Therapies for High Risk Neuroblastoma
title_fullStr	Monoclonal Antibody Therapies for High Risk Neuroblastoma
title_full_unstemmed	Monoclonal Antibody Therapies for High Risk Neuroblastoma
title_sort	monoclonal antibody therapies for high risk neuroblastoma
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/4d92fc6f80074bf6bbc35d6506e3485d
work_keys_str_mv	AT furmanwl monoclonalantibodytherapiesforhighriskneuroblastoma
_version_	1718385747039354880

Monoclonal Antibody Therapies for High Risk Neuroblastoma

Ejemplares similares